Hopp til hovedinnhold

Neglesopp - tinea unguium

Sist revidert:
Sist revidert av:


Definisjon:
Soppinfeksjon i neglene, som regel forårsaket av T. rubrum.
Forekomst:
Forekommer hos ca. 10%, og forekomsten øker med årene
Symptomer:
Klinisk diagnose kan være vanskelig. Neglesopp utgjør 50% av alle negleforandringene på tær
Funn:
Gir som regel matte, skjøre negler med gul misfarging, hyperkeratose, onycholyse. Etter hvert blir neglen fortykket og deformert
Diagnostikk:
Mikroskopering av avskrap i KOH-løsning, dyrkning eller PCR kan bekrefte diagnosen
Behandling:
Vanligvis ikke nødvendig. Ved sterkt behandlingsønske/subjektivt besvær er både lokal og systemisk behandling mulig. Sjansen for residiv er stor
  1. Westerberg DP, Voyack MJ. Onychomycosis: current trends in diagnosis and treatment. Am Fam Physician 2013; 88: 762-70. American Family Physician  
  2. Thomas J, Jacobson GA, Narkowicz CK, Peterson GM, Burnet H, Sharpe C. Toenail onychomycosis: an important global disease burden. J Clin Pharm Ther. 2010;35(5):497–519.
  3. Hartman TC, van Rijswijk E. Fungal nail infection. BMJ 2008; 337: a429. PubMed  
  4. Tosti A. Onychomycosis clinical presentation. Medscape, last updated Jul 13, 2017. emedicine.medscape.com  
  5. Garcia-Doval I, Cabo F, Monteagudo B, et al. Clinical diagnosis of onychomycosis is possible in some patients: cross-sectional diagnostic study and development of a diagnostic rule. Br J Dermatol 2010; 163: 743-51. PubMed  
  6. Walberg M, Mørk C, Sandven P, et al. 18S rDNA polymerase chain reaction and sequencing in onychomycosis diagnostics. Acta Derm Venereol 2006; 86: 223-6. PubMed  
  7. Saunte DML, Piraccini BM, Sergeev AY, et al. A survey among dermatologists: diagnostics of superficial fungal infections - what is used and what is needed to initiate therapy and assess efficacy? J Eur Acad Dermatol Venereol 2019; 33:421. PubMed  
  8. Tosti A. Dermatophyte infections. BestPractice, last updated 08 Nov 2022.
  9. Becker C, Bershow A. Lasers and photodynamic therapy in the treatment of onychomycosis: a review of the literature. Dermatol Online J 2013. pmid:24050286 PubMed  
  10. Kreijkamp-Kaspers S, Hawke KL, van Driel ML. Oral medications to treat toenail fungal infections. JAMA Clinicla Evidence Synopsis. JAMA 2018; 319: 397-8. pmid:29362778 PubMed  
  11. de Sá DC, Lamas AP, Tosti A. Oral therapy for onychomycosis: an evidence-based review. Am J Clin Dermatol. 2014 ;15(1):17-36. doi: 10.1007/s40257-013-0056-2.
  12. Piraccini BM, Sisti A, Tosti A. Long-term follow up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agentS. J Am Acad Dermatol 2010; 62: 411-4. PubMed  
  13. Friedlander SF, Chan YC, Chan YH, Eichenfield LF. Onychomycosis does not always require systemic treatment for cure: a trial using topical therapy. Pediatr Dermatol 2013; 30: 316-22. pmid:23278851 PubMed  
  14. Baran R, Tosti A, Hartmane I, et al. An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis. J Eur Acad Dermatol Venereol 2009; 23: 773-81. pmid:PMID: 19453778 PubMed  
  15. Iorizzo M, Hartmane I, Derveniece A, Mikazans I. Ciclopirox 8% HPCH nail laquer inthe treatment of mild-to-moderate onychomycosis: A randomized, double.blind amorolfine controlled study using a blinded evaluator. Skin Appedndage Disord 2015; 1: 134-40. doi:10.1159/000441569 DOI  
  16. Paul C, Coustou D, Lahfa M, et al. A multicenter, randomized, open-label, controlled study comparing the efficacy, safety and cost-effectiveness of a sequential therapy with RV4104A ointment, ciclopiroxolamine cream and ciclopirox film-forming solution with amorolfine nail lacquer alone in dermatophytic onychomycosis.. Dermatology 2013; 227 (2): 157-64. pmid:24051622 PubMed  
  17. Eisman S, Sinclair R. Fungal nail infection: diagnosis and management. BMJ. 2014 Mar 24;348:g1800. doi: 10.1136/bmj.g1800. DOI  
  18. Gupta AK, Simpson FC. New pharmacotherapy for the treatment of onychomycosis: an update. Expert Opin Pharmacother 2015; 16: 227-36. pmid:25522979 PubMed  
  19. Barot BS, Parejiya PB, Patel HK, et al. Drug delivery to the nail: therapeutic options and challenges for onychomycosis. Crit Rev Ther Drug Carrier Syst 2014; 31: 459-94. pmid:Crit Rev Ther Drug Carrier Syst
  20. Ma W, Si C, Kasyanju Carrero LM, et al. Laser treatment for onychomycosis: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98(48):e17948. PubMed  
  21. Goldstein AO, Bhatia N. Onychomycosis: Management. UpToDate, last updated Sep 08, 2022. UpToDate  
  22. Sotiriou E, Koussidou-Eremonti T, Chaidemenos G, et al. Photodynamic therapy for distal and lateral subungual toenail onychomycosis caused by Trichophyton rubrum: Preliminary results of a single-centre open trial. Acta Derm Venereol 2010; 90: 216. pmid:20169321 PubMed  
  • Tor Andre Johannessen, lege og redaktør NEL

Tidligere fagmedarbeidere

  • Morten Dalaker, avtalespesialist i hudsykdommer, Trondheim Hudlegesenter, Carl Johans gt 3, 7010 Trondheim
  • Sylvi Torvund, spesialist i allmennmedisin, Nardosletta legesenter, Trondheim